Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 combination therapy versus sintilimab + bevacizumab as first-line treatment for advanced hepatocellular carcinoma
CTR20232313Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706, sintilimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Qilu Pharmaceutical. Started Sep 2023; status: active.
02
Drugs
QL1706sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20232313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232313.